SPTLC2 Antibody (G-4): sc-398704

SPTLC2 Antibody (G-4) is a mouse monoclonal IgM antibody that detects SPTLC2 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-SPTLC2 antibody (G-4) is available as a non-conjugated format. SPTLC2, also known as serine palmitoyltransferase 2, plays a crucial role in sphingolipid biosynthesis, catalyzing the conversion of L-serine and palmitoyl-CoA into 3-oxosphinganine, a key precursor in the formation of complex sphingolipids. This process is vital for maintaining cellular membrane integrity and signaling, as sphingolipids are essential components of cell membranes and are involved in various cellular processes, including apoptosis, cell growth, and differentiation. Notably, dysregulation of SPTLC2 activity has been linked to several pathological conditions, including hereditary sensory neuropathy, atopic eczema, and psoriasis, highlighting the importance of SPTLC2 in both normal physiology and disease states. SPTLC2 (G-4) antibody serves as an invaluable tool for researchers studying the intricate mechanisms of sphingolipid metabolism and its implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SPTLC2 Antibody (G-4) References:

1. Increased expression of serine palmitoyltransferase (SPT) in balloon-injured rat carotid artery.  |  Uhlinger, DJ., et al. 2001. Thromb Haemost. 86: 1320-6. PMID: 11816724
2. Permeability barrier disruption increases the level of serine palmitoyltransferase in human epidermis.  |  Stachowitz, S., et al. 2002. J Invest Dermatol. 119: 1048-52. PMID: 12445191
3. Characterization of serine palmitoyltransferase in normal human tissues.  |  Batheja, AD., et al. 2003. J Histochem Cytochem. 51: 687-96. PMID: 12704216
4. Enhanced serine palmitoyltransferase expression in proliferating fibroblasts, transformed cell lines, and human tumors.  |  Carton, JM., et al. 2003. J Histochem Cytochem. 51: 715-26. PMID: 12754283
5. Activity of partially inhibited serine palmitoyltransferase is sufficient for normal sphingolipid metabolism and viability of HSN1 patient cells.  |  Dedov, VN., et al. 2004. Biochim Biophys Acta. 1688: 168-75. PMID: 14990347
6. Hepatic Expression of the Serine Palmitoyltransferase Subunit Sptlc2 Reduces Lipid Droplets in the Liver by Activating VLDL Secretion.  |  Kim, GT., et al. 2020. J Lipid Atheroscler. 9: 291-303. PMID: 32821738
7. Upregulation of the serine palmitoyltransferase subunit SPTLC2 by endoplasmic reticulum stress inhibits the hepatic insulin response.  |  Kim, GT., et al. 2022. Exp Mol Med. 54: 573-584. PMID: 35513574
8. Mutation screening of SPTLC1 and SPTLC2 in amyotrophic lateral sclerosis.  |  Li, C., et al. 2023. Hum Genomics. 17: 28. PMID: 36966328
9. Recurrent de novo SPTLC2 variant causes childhood-onset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesis.  |  Syeda, SB., et al. 2024. J Neurol Neurosurg Psychiatry. 95: 103-113. PMID: 38041679
10. Recurrent de-novo gain-of-function mutation in SPTLC2 confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis.  |  Dohrn, MF., et al. 2024. J Neurol Neurosurg Psychiatry. 95: 201-205. PMID: 38041684
11. SPTLC2 variants are associated with early-onset ALS and FTD due to aberrant sphingolipid synthesis.  |  Naruse, H., et al. 2024. Ann Clin Transl Neurol. 11: 946-957. PMID: 38316966
12. Human and murine serine-palmitoyl-CoA transferase--cloning, expression and characterization of the key enzyme in sphingolipid synthesis.  |  Weiss, B. and Stoffel, W. 1997. Eur J Biochem. 249: 239-47. PMID: 9363775

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-SPTLC2 Antibody (G-4) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-SPTLC2 Antibody (G-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

SPTLC2 Antibody (G-4) Specifications

Alternate Product Name: SPTLC2

Product Clone Name: G-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 306-342

Epitope Target: SPTLC2

Epitope Species: human

Product Reactivity/Detection: SPTLC2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for SPTLC2 Antibody (G-4): P: Blocking Peptide